Detection of cyclophosphamide-induced mutations at the Hprt but not the lacl locus in splenic lymphocytes of exposed mice

Environmental and Molecular Mutagenesis

Volumn 34, Issue 2-3, 1999, Pages 167-181

  Walker, Vernon E ^a,b   Andrews, Julie L ^c   Upton, Patricia B ^a   Skopek, Thomas R ^a   DeBoer, Johan G ^d   Walker, Dale M ^b   Shi, Xiaochu ^b   Sussman, Hillary E ^b   Gorelick, Nancy J ^c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b WADSWORTH CENTER   (United States)

^c PROCTER AND GAMBLE COMPANY   (United States)

^d UNIVERSITY OF VICTORIA   (Canada)

Author keywords

Cyclophosphamide; Hprt; lacl; Lymphocytes; Transgenic mice

Indexed keywords

CYCLOPHOSPHAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE MUTATION; MALE; MOUSE; MUTAGEN TESTING; NONHUMAN; RISK ASSESSMENT; SEQUENCE ANALYSIS; SPLEEN LYMPHOCYTE; TRANSGENE; TRANSGENIC MOUSE;

ANIMALS; BACTERIAL PROTEINS; BASE SEQUENCE; CELLS, CULTURED; CYCLOPHOSPHAMIDE; DNA; ESCHERICHIA COLI PROTEINS; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; MALE; MICE; MICE, TRANSGENIC; MUTATION; REPRESSOR PROTEINS; SPLEEN; T-LYMPHOCYTES;

EID: 0032699143     PISSN: 08936692     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2280(1999)34:2/3<167::AID-EM16>3.0.CO;2-O     Document Type: Article

References (50)

1. Aidoo A, Lyn-Cook LE, Mittelstaedt RA, Heflich RH, Casciano DA. 1991. Induction of 6-thioguanine-resistant lymphocytes in Fischer 344 rats following in vivo exposure to N-ethyl-N-nitrosourea and cyclophosphamide. Environ Mol Mutagen 17:141-151.
2. Ammenheuser MM, Ward JB Jr, Whorton EB Jr, Killian JM, Legator MS. 1988. Elevated frequencies of 6-thioguanine-resistant lymphocytes in multiple sclerosis patients treated with cyclophosphamide: a prospective study. Mutat Res 204:509-520.
3. Anderson D, Bishop JB, Garner RC, Ostrosky-Wegman P, Selby PB. 1995. Cyclophosphamide: review of its mutagenicity for an assessment of potential germ cell risks. Mutat Res 330:115-181.
4. 4 hotspot of Salmonella typhimurium hisD3052 carried on an M13 vector. J Biol Chem 267:22392-22400.
5. Benson AJ, Martin CN, Garner RC. 1988. N-(2-major hydroxyethyl)-N-[2-(7-guaninyl)ethyl]amine, the putative DNA adduct of cyclophosphamide in vitro and in vivo in the rat. Biochem Pharmacol 37:2979-2985.
6. Carr GJ, Gorelick NJ. 1994. Statistical tests of significance in transgenic mutation assays: considerations on the experimental unit. Environ Mol Mutagen 24:276-282.
7. Carr GJ, Gorelick NJ. 1996. Mutational spectra in transgenic animal research: data analysis and study design based upon the mutant or mutation frequency. Environ Mol Mutagen 28:405-413.
8. Cochrane JE, Skopek TR. 1994. Mutagenicity of butadiene and its epoxide metabolites: II. Mutational spectra of butadiene, 1,2-epoxybutene and diepoxybutane at the hprt locus in splenic T cells from exposed B6C3F1 mice. Carcinogenesis 15:719-723.
9. 2-propanodeoxyguanosine adducts in DNA upon reaction with 3-(N-carbethoxy-N-nitrosamino)propionaldehyde. Chem Res Toxicol 7:62-67.
10. Dempsey JL, Morley AA. 1986. Measurement of in vivo mutant frequency in lymphocytes in the mouse. Environ Mutagen 8:385-391.
11. Dycaico MJ, Provost GS, Kretz PL, Ransom SL, Moores JC, Short JM. 1994. The use of shuttle vectors for mutation analysis in transgenic mice and rats. Mutat Res 307:461-478.
12. Farabaugh PJ. 1978. Sequence of the lacl gene. Nature 274:765-769.
13. Gorelick NJ. 1995. Overview of mutation assays in transgenic mice for routine testing. Environ Mol Mutagen 25:218-230.
14. Gorelick NJ, O'Kelly JA, Gu M, Glickman BW. 1995. Mutational spectra in the lad gene in skin from 7,12-dimethylbenz[a]anthracene-treated and untreated transgenic mice. Mol Carcinog 14:53-62.
15. Gorelick NJ, Andrews JL, de Boer JG, Young R, Gibson DP, Walker VE. 1999. Tissue-specific mutant frequencies and mutational spectra in cyclophosphamide-treated LacI transgenic mice. Environ Mol Mutagen 34:154-166.
16. Heddle JA. 1999. Mutant manifestation: the time factor in somatic mutagenesis. Mutagenesis 14:1-3.
17. Hemminki K. 1985. Binding of metabolites of cyclophosphamide to DNA in a rat liver microsomal system and in vivo in mice. Cancer Res 45:4237-4243.
18. Hong PS, Chan KK. 1991. Enzymatic detoxification of phosphoramide mustard by soluble fractions from rat organ tissues. Drug Metab Dispos 19:568-573.
19. Hoorn AJW, Custer LL, Myhr BC, Brusick D, Gossen J, Vijg J. 1993. Detection of chemical mutagens using Muta® Mouse: a transgenic mouse model. Mutagenesis 8:7-10.
20. Hoyes KP, Wadeson PJ, Sharma HI, Hendry JH, Morris ID. 1998. Mutation studies in lacI transgenic mice after exposure to radiation or cyclophosphamide. Mutagenesis 13:607-612.
21. Hüttner E, Mergner U, Braun R, Schöneich J. 1990. Increased frequency of 6-thioguanine-resistant lymphocytes in peripheral blood of workers employed in cyclophosphamide production. Mutat Res 243:101-107.
22. International Agency for Research on Cancer (IARC). 1981. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, vol 26: Some anti-neoplastic and immunosuppressive agents. Lyon: IARC, pp 165-202.
23. Jones IM, Burkhart-Schultz K, Strout CL, Carrano AV. 1985. A method to quantify spontaneous and in vivo induced thioguanine-resistant mouse lymphocytes. Mutat Res 147:97-105.
24. Jones IM, Burkhart-Schultz K, Strout CL, Crippen TL. 1987. Factors that affect the frequency of thioguanine-resistant lymphocytes in mice following exposure to ethylnitrosourea. Environ Mutagen 9:317-329.
25. Kanekal S, Fraiser L, Kehrer JP. 1992. Pharmacokinetics, metabolic activation, and lung toxicity of cyclophosphamide in C57/BL6 and ICR mice. Toxicol Appl Pharmacol 114:1-8.
26. Kohler SW, Provost GS, Fieck A, Kretz PL, Bullock WO, Sorge JA, Putman DL, Short JM. 1991. Spectra of spontaneous and mutagen-induced mutations in the lacl gene in transgenic mice. Proc Natl Acad Sci U S A 88:7958-7962.
27. Melton DW, Konecki DS, Brennand J, Caskey CT. 1984. Structure, expression, and mutation of the hypoxanthine phosphoribosyltransferase gene. Proc Natl Acad Sci U S A 81:2147-2151.
28. Meng Q, Recio L, Reilly AA, Wong B, Bauer M, Walker VE. 1998. Comparison of the mutagenic potency of 1,3-butadiene at the hprt locus of T-lymphocytes following inhalation exposure of female B6C3F1 mice and F344 rats. Carcinogenesis 19:1019-1027.
29. Meng Q, Henderson RF, Chen T, Heflich RH, Walker DM, Bauer MJ, Reilly AA, Walker VE. 1999a. Mutagenicity of 1,3-butadiene at the Hpn locus of T-lymphocytes following inhalation exposures of female mice and rats. Mutat Res, in press.
30. Meng Q, Singh N, Heflich RH, Bauer MJ, Walker VE. 1999b. Comparison of the mutations at Hprt exon 3 of T-lymphocytes from B6C3F1 mice and F344 rats exposed by inhalation to 1,3-butadiene or the racemic mixture of 1,2:3,4-diepoxybutane. Mutat Res, submitted.
31. Mirkes PE, Brown NA, Kajbaf M, Lamb JH, Farmer PB, Naylor S. 1992. Identification of cyclophosphamide - DNA adducts in rat embryos exposed in vitro to 4-hydroperoxycyclophosphamide. Chem Res Toxicol 5:382-385.
32. Mirsalis JC, Monforte JA, Winegar RA. 1994. Transgenic animal models for measuring mutations in vivo. Crit Rev Toxicol 24:255-280.
33. 2-propanodeoxyguanosine. Proc Am Assoc Cancer Res 30:A555.
34. Myhr BC. 1991. Validation studies with Muta™ Mouse: A transgenic mouse model for detecting mutations in vivo. Environ Mol Mutagen 18:308-315.
35. 2-propanodeoxyguanosine adducts as common DNA lesions in rodents and humans. Proc Natl Acad Sci U S A 91:7491-7495.
36. Provost GS, Short JM. 1994. Characterization of mutations induced by ethylnitrosourea in seminiferous tubule germ cells of transgenic B6C3F1 mice. Proc Natl Acad Sci U S A 91:6564-6568.
37. Provost GS, Kretz PL, Hamner RT, Matthews CD, Rogers BJ, Lundberg KS, Dycaico MJ, Short JM. 1993. Transgenic systems for in vivo mutation analysis. Mutat Res 288:133-150.
38. Sisk S, Pluta LJ, Meyer KG, Wong BC, Recio L. 1997. Assessment of the in vivo mutagenieity of ethylene oxide in the tissues of B6C3F1 lacI transgenic mice following inhalation exposure. Mutat Res 391: 153-164.
39. Skopek TR. 1995. Of mice and men: target size and sensitivity. Mutat Res 331:225-228.
40. Skopek TR, Walker VE, Cochrane JE, Craft TR, Cariello NF. 1992. Mutational spectrum at the Hprt locus in splenic T cells of B6C3F1 mice exposed to N-ethyl-N-nitrosourea. Proc Natl Acad Sci U S A 89:7866-7870.
41. Skopek TR, Kort KL, Marino DR. 1995. Relative sensitivity of the endogenous hprt gene and lacl transgene in ENU-treated Big Blue™ B6C3F1 mice. Environ Mol Mutagen 26:9-15.
42. Skopek TR, Kort KL, Marino DR, Mittal LV, Umbenhauer DR, Laws GM, Adams SP. 1996. Mutagenic response of the endogenous hprt gene and lacl transgene in benzo[a]pyrene-treated Big Blue® B6C3F1 mice. Environ Mol Mutagen 28:376-384.
43. Swenberg JA, Fedtke N, Fennell TR, Walker VE. 1990. Relationships between carcinogen exposure, DNA adducts and carcinogenesis. In Clayson DB, Munro IC, Shubik P, Swenberg JA (eds): Progress in predictive toxicology. Amsterdam: Elsevier, pp 161-184.
44. Tao KS, Urlando C, Heddle JA. 1993. Comparison of somatic mutation in a transgenic versus host locus. Proc Natl Acad Sci U S A 90:10681-10685.
45. Walker VE, Skopek TR. 1993. A mouse model for the study of in vivo mutational spectra: Sequence specificity of ethylene oxide at the hprt locus. Mutat Res 288:151-162.
46. Walker VE, Gorelick NJ, O'Kelly JA, Craft TR, deBoer J, Glickman BW, Skopek TR. 1994. Frequency and spectrum of ethylnitrosourea induced mutation at the hprt and lad loci in splenic T-cells of exposed Big Blue® mice. Environ Mol Mutagen 23(suppl 23):71.
47. Walker VE, Gorelick NJ, Andrews JA, Craft TR, deBoer J, Glickman BW, Skopek TR. 1996. Frequency and spectrum of ethylnitrosourea induced mutation at the hprt and lad loci in splenic T-cells of exposed lacl transgenic mice. Cancer Res 56:4654-4661.
48. Walker VE, Sisk SC, Upton PB, Wong BA, Recio L. 1997. In vivo mutagenieity of ethylene oxide at the hprt locus in T-lymphocytes of B6C3F1 lacl transgenic mice following inhalation exposure. Mutat Res 392:211-222.
49. Walker VE, Jones IM, Crippen TL, Meng Q, Walker DM, Bauer MJ, Reilly AA, Tates AD, Nakamura J, Upton PB, Skopek TR. 1999. Relationships between exposure, cell loss and proliferation, and manifestation of Hprt mutant T-cells following treatment of preweanling, weanling, and adult male B6C3F1 mice with N-ethyl-N-nitrosourea. Mutat Res, in press.
50. Winegar RA, Lutze LH, Hamer JD, O'Loughlin KG, Miralis JC. 1994. Radiation-induced point mutations, deletions and micronuclei in lacl transgenic mice. Mutat Res 307: 479-487.